施贵宝公司宣布,其药物Mezikd在治疗复发或难治性多发性骨髓瘤的临床试验中,取得了显著成果。数据显示,与现行标准疗法相比,Mezikd能够将患者的疾病进展或死亡风险降低超过50%。这一结果凸显了该药物在改善这类难治性血液癌症患者临床结局方面的巨大潜力。
施贵宝公司宣布,其药物Mezikd在治疗复发或难治性多发性骨髓瘤的临床试验中,取得了显著成果。数据显示,与现行标准疗法相比,Mezikd能够将患者的疾病进展或死亡风险降低超过50%。这一结果凸显了该药物在改善这类难治性血液癌症患者临床结局方面的巨大潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.